Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > pregnancy

: Category C

or Not relevant (geriatric problem)

Use the filters below to narrow your results.

Bisoprolol (1) · Dexmethylphenidate (1) · Duloxetine (1) · Haloperidol (1) · Memantine ER / Donepezil (1) · Metoprolol (1) · Mixed amphetamine salts (1) · Nebivolol (1) · Prazosin (1) · Propranolol (1) · Sodium Oxybate (1)

Adderall, Adderall XR, Mydayis (1) · Bystolic (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Focalin, Focalin XR (1) · Haldol, Serenace, Haldol Decanoate (1) · Inderal (1) · Lopressor (tartrate), Toprol XL (succinate) (1) · Minipress (1) · Namzaric (1) · Xyrem; Xywav (lower-sodium formulation with Ca/Mg/K salts) (1) · Zebeta (1)

Alpha-1 Adrenergic Antagonist (1) · Amphetamine (1) · Antidepressant (1) · Antiemetic (1) · Anxiolytic (1) · Beta Blocker (4) · Cardioselective (β1) (2) · Cardioselective (β1) + vasodilator (1) · CNS stimulant (1) · Combined cholinesterase inhibitor + NMDA antagonist (1) · GABAB Agonist; Endogenous GHB receptor agonist (1) · NDRI (1) · Non-selective (1) · Psychostimulant (2) · SNRI (1) · Typical antipsychotic (1)

Agonist at the metabotropic GABAB receptor and the endogenous γ-hydroxybutyrate (GHB) receptor. Produces deep sleep with increased slow-wave architecture, suppression of REM intrusion, and cataplexy reduction. (1) · Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) · Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. (1) · High-affinity D2 receptor antagonist (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1)

None (3) · 1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) · 10–40 mg (situational anxiety); 40 mg BID (HTN) (1) · 2.25 g at bedtime + 2.25 g 2.5–4 h later; titrate weekly to 6–9 g/night total (1) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) · 5 mg daily (1) · For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength (1)

None (3) · 0.5 g/mL oral solution (1) · 1, 2, 5 mg caps (1) · 10, 20, 40, 60, 80 mg tabs; 60/80/120/160 mg ER caps; 1 mg/mL IV (1) · 2.5, 5, 10, 20 mg tabs (1) · 5, 10 mg tabs (1) · 7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1) · Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)

None (3) · 20 mg/d (1) · 28/10 mg/d (1) · 40 mg/d (2) · 400 mg/d (1) · 640 mg/d (HTN); 240 mg/d (migraine) (1) · 9 g/night (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

IM (1) · IV (3) · Oral (9) · Oral (capsule whole or opened/sprinkled on applesauce) (1) · Oral (must be taken in bed; effects within minutes) (1)

15–30 min (fasting) (1) · 1–2 h (2) · 1–2 h (PO), immediate (IV) (1) · 1–2 h (PO); immediate (IV) (1) · 30–60 min (1) · 30–90 min (1) · Component effects accumulate over weeks (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · PO 1–2 h; IM 30–60 min; IV 5–20 min (1)

12–24 h (oral); decanoate IM 3–4 weeks (1) · 24 h (3) · 6–12 h (IR); 24 h (ER) (1) · 6–12 h (tartrate); 24 h (succinate) (1) · 6–8 h (1) · Chronic daily dosing (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1) · IR 4–6 h; XR 8–12 h (1) · ~3 h per dose (twice-nightly schedule required) (1)

14–26 h (oral); ~3 weeks (decanoate) (1) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (1) · 30–60 min (1) · 3–6 h (1) · 3–7 h (1) · 9–12 h (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~12 hours (1) · ~60–80 h (memantine); ~70 h (donepezil) (1)

~100% both components (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~22–25% (1) · ~25% (extensive hepatic first-pass) (1) · ~25% (high first-pass) (1) · ~50% (1) · ~50% (highly variable) (1) · ~60% (1) · ~60–70% (oral) (1) · ~75–90% (oral) (1) · ~90% (low first-pass) (1)

Rx-only (2) · Rx-only in US (6) · Schedule II (2) · Schedule III; REMS-restricted (Schedule I if outside the pharmaceutical channel, same molecule as illicit GHB) (1)

Showing below up to 11 results in range #1 to #11.

B

Bisoprolol

D

H

Haloperidol

M

N

Nebivolol

P

S

Sodium Oxybate